Hualan Biological Engineering (002007) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was ¥1.84 billion, down 21.04% year-over-year; YTD revenue was ¥3.49 billion, down 10.79% year-over-year.

• Net profit attributable to shareholders for Q3 was ¥483 million, down 10.58% year-over-year; YTD net profit was ¥924 million, down 13.46%.

• Operating cash flow for Q3 was ¥460 million, a decrease of 33.63% compared to the same period last year.

Financial highlights

• Basic EPS for Q3 was ¥0.2650, down 10.56% year-over-year; YTD basic EPS was ¥0.5056, down 13.57%.

• Gross margin and operating profit details not explicitly stated, but sales expenses fell 31.11% and financial expenses decreased 680.02% due to higher interest income.

• Non-recurring gains for Q3 totaled ¥28.85 million, mainly from fair value changes and government subsidies.

Outlook and guidance

• No explicit forward-looking guidance provided, but management notes significant changes in prepayments, other receivables, and cash flows due to operational adjustments.